-- 根據週二提交給香港交易所的文件，阿爾法瑪腫瘤（HKG:9966）預計2025年將虧損1.139億元人民幣，而去年同期則獲利1.663億元。 這家癌症治療藥物研發公司的股價在周三上午的交易中下跌超過3%。 每股虧損0.12元人民幣，而去年同期獲利0.17元。 數據顯示，2025年營收將從2024年的6.401億元降至5.662億元。
Related Articles
Asia
MOG Digitech Chairman Resigns; Co-CEO Assumes CEO Role
MOG Digitech (HKG:1942) announces Deng Zhihua's resignation as its chairman and co-CEO effective Tuesday.The move allows Mr. Deng to dedicate more time to his other commitments, according to a Tuesday Hong Kong bourse filing.Shares of the fintech company were up 1% in Wednesday afternoon trading.Co-CEO Chen Yongzhong was also appointed as the company's CEO, starting on the same day.The firm is currently in the process of identifying a suitable candidate for the chair position.
$HKG:1942
Asia
Genertec Universal Medical's Profit Rises 5% in Q1
Genertec Universal Medical (HKG:2666) said profit attributable to ordinary shareholders rose about 4.8% year over year in the first quarter, according to a Hong Kong bourse filing.Revenue fell about 4.5% from a year earlier.The group said its integrated healthcare business saw outpatient and emergency visits rise about 4.5% year over year, while health check-up revenue increased about 13.3%.
$HKG:2666
Asia
Jefferies Adjusts The Phoenix Mills' Price Target to INR2,085 from INR2,000, Keeps at Buy
$BOM:503100$NSE:PHOENIXLTD